May 17, 2012 by Brian Orelli, PhDShould Investors Worry About Arena's Offering?Raise cash when possible.
May 16, 2012 by Brian Orelli, PhDYour Warning Label Is My Sales BrochureGilenya gets a new warning label.
May 16, 2012 by Brian Orelli, PhD2 Reasons That Cystic Fibrosis Trumps Hep CVertex jumps on new cystic fibrosis data.
May 16, 2012 by Brian Orelli, PhDAbbott Stands Up to ObamacareYou can't make it without our secrets, and we're not telling.
May 16, 2012 by Brian Orelli, PhDDrug Fails: At Least It's Approved AlreadyPfizer's Torisel fails to best Nexavar in a head-to-head trial.
May 15, 2012 by Brian Orelli, PhDThis Biotech's for Sale! Reportedly.Bloomberg reports on Amylin's potential suitors.
May 14, 2012 by Brian Orelli, PhDA Step Closer to Quadrific SalesGilead's Quad easily gets past the FDA advisory panel.
May 12, 2012 by Brian Orelli, PhDDrug Approval! Oh, Wait, We Knew That Already.Cell Therapeutics shares jump on a non-event.
May 11, 2012 by Brian Orelli, PhDHostile Takeover? More Like Nice Guy Showdown.Glaxo takes off the gloves and puts on oven mitts in bid to get Human Genome Sciences.
May 11, 2012 by Brian Orelli, PhDLet the Obesity-Drug Wars BeginArena gets a solid endorsement from the FDA advisory panel.
May 10, 2012 by Brian Orelli, PhDAn Arena of Obesity QuestionsArena's obesity drug, lorcaserin, heads back in front of an FDA advisory panel.
May 10, 2012 by Brian Orelli, PhDA Much-Needed Win for PfizerFDA advisory panel recommends approving rheumatoid arthritis drug tofacitinib.
May 9, 2012 by Brian Orelli, PhD1 Biotech With 2 Binary Events in 2 DaysTwo of Gilead's HIV drugs head in front of FDA advisory committee meetings.
May 8, 2012 by Brian Orelli, PhDPfizer's Must-Win FDA VoteRheumatoid arthritis drug tofacitinib could be a blockbuster.
May 8, 2012 by Brian Orelli, PhDCan Dendreon's New Management Turn Things Around?It's too early to tell.
May 4, 2012 by Brian Orelli, PhDTysabri's Looking Good at a CrossroadsSales up despite potential to lose half the patients.
May 3, 2012 by Brian Orelli, PhDWill the FDA Approve Alexza's Adasuve?Seems unlikely, given the data.
May 2, 2012 by Brian Orelli, PhDPfizer Looks Fine Post-TornadoEarnings statement gets jumbled up post-Lipitor, breakup.
